NCT04542369View on ClinicalTrials.gov

Pilot Study of PD-1inhibitor (Tislelizumab) Plus Chemotherapy as Neoadjuvant Therapy for Limited-Stage Small-Cell Lung Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 1, 2021

Primary Completion Date

December 31, 2023

Study Completion Date

November 30, 2025

Conditions
Small-cell Lung Cancer
Interventions
DRUG

Tislelizumab (BGB-A317) Plus Chemotherapy (Cisplatin/Carboplatin and Etoposide)

Inductive/neoadjuvant therapy: Tislelizumab + EP Maintenance/adjuvant therapy: Tislelizumab + EP

Trial Locations (1)

200433

RECRUITING

Shanghai Pulmonary Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Pulmonary Hospital, Shanghai, China

OTHER